Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday

Blueprint Medicines (BPMC) shares surged 26.09% to $127.79 on Monday after Sanofi announced it would acquire the company for $9.1 billion, offering $129 per share, a 27% premium over Blueprint's closing price on May 30, 2025. The deal includes a contingent value right (CVR) potentially worth $6 per share tied to future milestones for BLU-808, and gives Sanofi access to Ayvakit/Ayvakyt (avapritinib), a treatment for advanced and indolent systemic mastocytosis.

Analysis

Blueprint Medicines Corporation (NASDAQ:BPMC) experienced a significant stock price appreciation, surging 26.09% to close at $127.79 on Monday, following the announcement of its acquisition by French pharmaceutical giant Sanofi. The definitive agreement values Blueprint Medicines at $9.1 billion, with Sanofi set to commence a tender offer to acquire BPMC shares at $129 apiece in cash. This offer price represents a notable premium of 27% over Blueprint’s closing price on May 30, 2025, and approximately 34% over its 30-day volume-weighted average price (VWAP) as of that date. In addition to the cash consideration, BPMC shareholders will receive one non-tradable contingent value right (CVR) per share, entitling them to potential future payments of $2 and $4 per CVR upon achievement of specified development and regulatory milestones for BLU-808. The acquisition will also transfer ownership of Blueprint's key commercial asset, Ayvakit/Ayvakyt (avapritinib), an approved medicine for advanced and indolent systemic mastocytosis, strengthening Sanofi's rare disease portfolio. The market's reaction, as evidenced by BPMC's stock surge to near the offer price, reflects strong approval of the deal terms and a high perceived likelihood of completion.

Key Decisions for Investors

• BPMC shareholders should evaluate the current market price of $127.79 against the $129 per share cash offer, considering the small remaining spread and the additional potential value from the contingent value right (CVR) linked to BLU-808 milestones.
• Investors holding BPMC may consider the merits of holding shares through the acquisition to receive the full cash offer and the CVR, versus selling at current market levels to realize immediate gains, noting that the primary upside beyond the cash offer is contingent.
• Monitoring regulatory approvals for the Sanofi-Blueprint Medicines transaction and tracking clinical development progress for BLU-808 are crucial for BPMC shareholders to assess the probability and timing of receiving CVR payments.